Literature DB >> 22225648

Long-term impact of liver transplantation on respiratory function and nutritional status in children and adults with cystic fibrosis.

J K Dowman1, D Watson, S Loganathan, B K Gunson, J Hodson, D F Mirza, J Clarke, C Lloyd, D Honeybourne, J L Whitehouse, E F Nash, D Kelly, I van Mourik, P N Newsome.   

Abstract

Early liver transplant (LT) has been advocated for patients with cystic fibrosis liver disease (CFLD) and evidence of deterioration in nutritional state and respiratory function to prevent further decline. However, the impact of single LT on long-term respiratory function and nutritional status has not been adequately addressed. We performed a retrospective analysis of the outcomes of 40 (21 adult/19 pediatric) patients with CFLD transplanted between 1987 and 2009 with median follow-up of 47.8 months (range 4-180). One and five-year actuarial survival rates were 85%/64% for adult and 90%/85% for pediatric LT cohorts, respectively. Lung function remained stable until 4 years (FEV(1) % predicted; pretransplant 48.4% vs. 45.9%, 4 years posttransplant) but declined by 5 years (42.4%). Up to 4 years posttransplant mean annual decline in FEV(1) % was lower (0.74%; p = 0.04) compared with the predicted 3% annual decline in CF patients with comorbidity including diabetes. Number of courses of intravenous antibiotics was reduced following LT, from 3.9/year pretransplant to 1.1/year, 5 years posttransplant. Body mass index was preserved posttransplant; 18.0 kg/m(2) (range 15-24.3) pretransplant versus 19.6 kg/m(2) (range 16.4-22.7) 5 years posttransplant. In conclusion, LT is an effective treatment for selected patients with cirrhosis due to CFLD, stabilizing aspects of long-term lung function and preserving nutritional status. © Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2012        PMID: 22225648     DOI: 10.1111/j.1600-6143.2011.03904.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

Review 1.  Hepatic Manifestations of Cystic Fibrosis.

Authors:  Sasan Sakiani; David E Kleiner; Theo Heller; Christopher Koh
Journal:  Clin Liver Dis       Date:  2019-02-21       Impact factor: 6.126

2.  Liver transplantation and cell therapies for inborn errors of metabolism.

Authors:  Patrick McKiernan
Journal:  J Inherit Metab Dis       Date:  2013-01-08       Impact factor: 4.982

Review 3.  Cystic fibrosis liver disease: A condition in need of structured transition and continuity of care.

Authors:  Julian Hercun; Fernando Alvarez; Catherine Vincent; Marc Bilodeau
Journal:  Can Liver J       Date:  2019-08-27

Review 4.  Interventions for preventing and managing advanced liver disease in cystic fibrosis.

Authors:  Senthil K Palaniappan; Nan Nitra Than; Aung Win Thein; Soe Moe; Indra van Mourik
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29

5.  Cystic Fibrosis Associated with Worse Survival After Liver Transplantation.

Authors:  Sylvester M Black; Frederick W Woodley; Dmitry Tumin; Khalid Mumtaz; Bryan A Whitson; Joseph D Tobias; Don Hayes
Journal:  Dig Dis Sci       Date:  2015-11-24       Impact factor: 3.199

6.  Cystic fibrosis related liver disease and endocrine considerations.

Authors:  Jordan S Sherwood; Jagdeesh Ullal; Katherine Kutney; Kara S Hughan
Journal:  J Clin Transl Endocrinol       Date:  2021-12-13

Review 7.  Cystic fibrosis associated liver disease in children.

Authors:  Joseph J Valamparampil; Girish L Gupte
Journal:  World J Hepatol       Date:  2021-11-27

8.  Practical guidelines: lung transplantation in patients with cystic fibrosis.

Authors:  T O Hirche; C Knoop; H Hebestreit; D Shimmin; A Solé; J S Elborn; H Ellemunter; P Aurora; M Hogardt; T O F Wagner
Journal:  Pulm Med       Date:  2014-03-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.